Collegium Pharma (COLL): Management Changes A Positive - Needham
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street to higher close as SpaceX, Super Micro boost AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
Collegium Pharma (COLL) Secures Additional Managed Care Coverage for Xtampza ER for Medicare Part D Patients
June 1, 2017 7:13 AM EDTCollegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced that one of the largest managed care organizations with approximately 8 million Medicare Part D lives has added Xtampza® ER to its Medicare Part D formularies. Effective June 1, 2017, Xtampza ER is the exclusive oxycodone extended-release product for this... More



